BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Pelletier AL, Nicaise-Roland P. Adalimumab and pharmacokinetics: Impact on the clinical prescription for inflammatory bowel disease. World J Pharmacol 2016; 5(1): 44-50 [DOI: 10.5497/wjp.v5.i1.44]
URL: https://www.wjgnet.com/1007-9327/full/v5/i1/44.htm
Number Citing Articles
1
Cátia Rocha, Joana Afonso, Paula Lago, Bruno Arroja, Ana I. Vieira, Claudia C. Dias, Fernando Magro. Accuracy of the new rapid test for monitoring adalimumab levelsTherapeutic Advances in Gastroenterology 2019; 12: 175628481982823 doi: 10.1177/1756284819828238
2
Neeraj Narula, Brian Lauzon, John K. Marshall. Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel diseaseScandinavian Journal of Gastroenterology 2019; 54(6): 712 doi: 10.1080/00365521.2019.1621367